Japonsko - angličtina - すりの適正使用協議会 RAD-AR Council, Japan

towa pharmaceutical co., ltd. - raloxifene hydrochloride - white oval tablet, major axis: approx.12.1mm, minor axis: approx. 6.6mm

Japonsko - angličtina - すりの適正使用協議会 RAD-AR Council, Japan

sawai pharmaceutical co.,ltd. - raloxifene hydrochloride - white tablet, major axis: 12.2 mm, minor axis: 6.6 mm, thickness: 4.5 mm

Japonsko - angličtina - すりの適正使用協議会 RAD-AR Council, Japan

nichi-iko pharmaceutical co.,ltd - raloxifene hydrochloride hydrate - white oval tablet, major axis: 12.2 mm, minor axis: 6.6 mm, thickness: 4.6 mm

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - conjugated estrogens, quantity: 0.45 mg; bazedoxifene acetate, quantity: 22.56 mg (equivalent: bazedoxifene, qty 20 mg) - tablet, modified release - excipient ingredients: lactose monohydrate; hypromellose; microcrystalline cellulose; hyprolose; macrogol 400; magnesium stearate; sucrose palmitate; ascorbic acid; powdered cellulose; calcium phosphate; sucrose; propylene glycol; purified water; isopropyl alcohol; iron oxide black; titanium dioxide; iron oxide red; polydextrose; povidone; hyetellose; maltitol solution; poloxamer - duavive is indicated for treatment of moderate to severe vasomotor symptoms associated with menopause in women with a uterus.,- duavive should be used for the shortest duration consistent with treatment goals and risks for the individual woman.,- experience in women older than 65 years is limited.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - raloxifene hydrochloride -

Spojené státy - angličtina - NLM (National Library of Medicine)

lake erie medical & surgical supply dba quality care products llc - raloxifene hydrochloride (unii: 4f86w47br6) (raloxifene - unii:yx9162eo3i) - raloxifene hydrochloride 60 mg

Spojené státy - angličtina - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - raloxifene hydrochloride (unii: 4f86w47br6) (raloxifene - unii:yx9162eo3i) - raloxifene hydrochloride 60 mg

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

aurobindo pharma australia pty ltd - raloxifene hydrochloride -

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - raloxifene hydrochloride, quantity: 60 mg - tablet, film coated - excipient ingredients: crospovidone; polysorbate 80; magnesium stearate; lactose monohydrate; lactose; povidone; carnauba wax; colour; propylene glycol; indigo carmine; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; industrial methylated spirit; ethanol - evista is indicated for the prevention and treatment of osteoporosis in post-menopausal women. evista is indicated for the reduction in the risk of invasive breast cancer in postmenopausal women with osteoporosis. evista is indicated for the reduction in the risk of invasive breast cancer in postmenopausal women at high risk of invasive breast cancer. high risk of breast cancer is defined as at least one breast biopsy showing lobular carcinoma in situ (lcis) or atypical hyperplasia, one or more first-degree relatives with breast cancer, or a 5-year predicted risk of breast cancer >1.66% (based on the modified gail model). among the factors included in the modified gail model are the following: current age, number of first-degree relatives with breast cancer, number of breast biopsies, age at menarche, nulliparity or age of first live birth. currently, no single clinical finding or test result can quantify risk of breast cancer with certainty.

Izrael - angličtina - Ministry of Health

teva pharmaceutical indust.ltd - raloxifene hydrochloride 60 mg - tablets - raloxifene - - treatment of osteoporosis in post menopausal women. - prevention of osteoporosis in post menopausal women .